• PPT in ERα Signaling: From Ligand to LUAD Assay

  2026-08-23

  PPT (Propyl Pyrazole Triol) enables selective ERα perturbation rather than simple receptor correlation. This article translates evidence from female lung adenocarcinoma research into a practical framework for designing, controlling, and interpreting ERα signaling assays.

• MCC950 sodium: NLRP3 Workflow and Troubleshooting

  2026-08-22

  MCC950 sodium, also known as CRID3 sodium salt, provides selective control of NLRP3 signaling for macrophage assays, cytokine profiling, and disease-model studies. This guide connects practical dose optimization with the emerging astrocyte biology of morphine tolerance and highlights troubleshooting strategies for reproducible results.

• SB-505124 hydrochloride for TGF-β assays

  2026-08-21

  SB-505124 hydrochloride provides reversible, selective control of ALK4, ALK5, and ALK7 signaling for fibrosis, epithelial, and mechanobiology workflows. This guide connects Smad2/3 pathway assays with practical viability, gel-release, glaucoma, and cancer-cell stiffness experiments while clearly separating established evidence from testable extensions.

• Flavopiridol (L868275): CDK Inhibition Guide

  2026-08-20

  Flavopiridol, also known as L868275, is a pan-cyclin-dependent kinase inhibitor used to study cell-cycle control, apoptosis, and transcription. Its reported nanomolar kinase potency and preclinical antitumor activity support use as a cancer research tool, but product specifications and disease-model evidence should not be conflated.

• EdU Flow Cytometry Kits for Mechanistic Studies

  2026-08-20

  EdU Flow Cytometry Assay Kits enable quantitative S-phase analysis without DNA denaturation. This article shows how the K1077 workflow can connect cell-cycle phenotypes with pathway-level pharmacology in lung adenocarcinoma research.

• HMGCS2, LysoPC, and Pulmonary Fibrosis

  2026-08-19

  Yang et al. identify injured type II alveolar epithelial cells as a major source of accumulated lysophosphatidylcholine and show that HMGCS2 loss links epithelial lipid dysregulation to fibroblast activation. Their combined lipidomic, transcriptomic, genetic, and mouse-model experiments define a mechanistic pathway involving PPARα, CPT1A, and CPT2 that may guide future pulmonary fibrosis research.

• KPT-330: Designing XPO1–Platinum Studies

  2026-08-19

  KPT-330 (Selinexor) enables a focused strategy for studying XPO1 inhibition and platinum sensitivity in DLBCL. This guide translates recent combination data into assay decisions, mechanistic readouts, controls, and reproducible handling practices for cancer research.

• Annexin V Workflow for Apoptosis Research

  2026-08-18

  Build a flexible Annexin V workflow for detecting phosphatidylserine externalization, comparing early apoptosis with membrane-disruptive cell death, and studying phospholipid-dependent coagulation. The unlabeled recombinant format also supports custom conjugation and competition-binding experiments when commercial fluorescent Annexin V conjugates are not ideal.

• IEM-1925 and Soman-Induced Status Epilepticus

  2026-08-18

  The 2026 NeuroToxicology study evaluated IEM-1925, a dual AMPA/NMDA glutamate receptor antagonist, in a rat model of soman-induced status epilepticus. Its combination of seizure control, hippocampal protection, and behavioral improvement supports broad glutamate-receptor blockade as a strategy for organophosphorus nerve-agent neurotoxicity, while also highlighting the limits of translating an in vivo dual-target result to AMPA-selective tools.

• PPT1–SPRY4 Palmitoylation in Cisplatin-Resistant OS

  2026-08-17

  Huang and colleagues identify a dynamic SPRY4 palmitoylation–depalmitoylation cycle controlled by ZDHHC7 and PPT1 as a regulator of MAPK signaling and cisplatin resistance in osteosarcoma. Their data support PPT1 inhibition with GNS561 as a mechanistically informed combination strategy that may restore cisplatin sensitivity, although clinical validation remains necessary.

• BH3 Mimetics and Senescent Breast Cancer Cells

  2026-08-17

  The reference study shows that chemotherapy-induced senescent cells in TP53 wild-type breast cancer can remain viable, secrete tumor-promoting factors, and contribute to relapse. Its key innovation is the use of BH3 mimetics to selectively eliminate this residual population, revealing that BCL-XL or combined BCL-XL/MCL1 dependence determines senolytic response.

• SLU-PP-332 Workflow for ERR Metabolism Research

  2026-08-16

  SLU-PP-332 provides a practical way to interrogate ERR-driven mitochondrial remodeling, linking receptor pharmacology with respiration, fatty-acid oxidation, and glucose-regulation assays. This workflow emphasizes concentration control, orthogonal readouts, and careful separation of pan-ERR biology from translational claims.

• Annexin V in Myocardial I/R Cell-Death Research

  2026-08-15

  This study established labeled recombinant human Annexin V as an in situ probe for detecting phosphatidylserine exposure during cardiomyocyte injury after myocardial ischemia and reperfusion. Its time-resolved measurements showed that Annexin V-positive cardiomyocytes increased with longer ischemic or reperfusion intervals and decreased markedly after cell-death pathway intervention, supporting its use in mechanistic and therapeutic-window studies.

• Disulfiram: From Proteasome Stress to Synthetic Lethality

  2026-08-15

  Disulfiram is moving from its established role in alcohol metabolism into a broader translational framework spanning ALDH2-dependent redox stress, proteasomal chymotrypsin-like activity inhibition, and genotype-selective apoptotic cancer cell death induction. This article connects evidence from APC-deficient colorectal cancer and breast cancer MDA-MB-231 models with practical guidance for designing rigorous, mechanism-aware studies.

• VX-702: Selective p38α MAPK Research Workflows

  2026-08-14

  VX-702 enables controlled p38α MAPK inhibition across cytokine, platelet, arthritis, and cardiac injury workflows. Its ATP-competitive profile, strong biochemical potency, and compatibility with mechanistic dephosphorylation assays make it useful for separating pathway-specific effects from broader stress responses.

451 records 7/31 page Previous Next First page 上5页 678910 下5页 Last page